Heart Failure | Resting Vasoconstriction, | Defect in NO/cGMP mediated vasodilatation; ?Decrease in LZ+ MYPT1 | Vasodilators (ACE inhibitors, ARBs, hydralazine, nitrates) |
Decrease in sensitivity to NO |
Idiopathic Pulmonary Hypertension | Pulmonary Vascular Vasoconstriction & | Proliferation of pulmonary SMCs, Defect in NO/cGMP mediated vasodilatation. ?Decrease in LZ+ MYPT1 and increase in NM myosin | Prostaglandins (Epoprostenol), Phosphodiesterase inhibitors (Sildenafil), Guanylate cyclase stimulators (Riocigaut), Endothelin antagonists (Bosentan), NO inhalation & Rho kinase inhibitors (Fasudil) |
Decrease in sensitivity to NO |
Portal Hypertension | Sensitivity to vasodilators increased & to vasoconstrictors decreased | ?Changes in isoform expression of contractile proteins which influence both smooth muscle activation and relaxation | Management of fluid status |
Raynaud’s Phenomenon | Transient vasospasm of digital vessels | Altered reactivity of vascular smooth muscle | Keeping digits warm, CCBs |
Pre-eclampsia/Pregnancy Induced Hypertension | Increase in vascular tone | Altered reactivity to RhoA, PKC & Ca2+, decrease NO | Antihypertensives (non-fetotoxic) |